References
|
1. |
|
Christophersen, AS. Amphetamine designer drugs - an overview and epidemiology. Toxicol Lett 2000; 112-113:127. |
|
2. |
|
Beebe, DK, Walley, E. Substance abuse: the designer drugs. Am Fam Physician 1991; 43:1689. |
|
3. |
|
Rattray, M. Ecstasy: Towards an understanding of the biochemical basis of the actions of MDMA. Essays Biochem 1991; 26:77. |
|
4. |
|
Buchert, R, Thomasius, R, Nebeling, B, et al. Long-term effects of "ecstasy" use on serotonin transporters of the brain investigated by PET. J Nucl Med 2003; 44:375. |
|
5. |
|
Randall, T. Ecstasy-fueled 'rave' parties become dances of death for English youths. JAMA 1992; 268:1505. |
|
6. |
|
Cregg, MT, Tracey, JA. Ecstasy abuse in Ireland. Ir Med J 1993; 86:118. |
|
7. |
|
Strote, J, Lee, JE, Wechsler, H. Increasing MDMA use among college students: results of a national survey. J Adolesc Health 2002; 30:64. |
|
8. |
|
Melian, AM, Burillo-Putze, G, Campo, CG, et al. Accidental ecstasy poisoning in a toddler. Pediatr Emerg Care 2004; 20:534. |
|
9. |
|
Bedford Russell, AR, Schwartz, RH, Dawling, S. Accidental ingestion of 'Ecstasy' (3,4-methylenedioxymethylamphetamine). Arch Dis Child 1992; 67:1114. |
|
10. |
|
Cooper, AJ, Egleston, CV. Accidental ingestion of Ecstasy by a toddler: unusual cause for convulsion in a febrile child. J Accid Emerg Med 1997; 14:183. |
|
11. |
|
Cuomo, MJ, Dyment, PG, Gammino, VM. Increasing use of 'Ecstasy' (MDMA) and other hallucinogens on a college campus. J Am Coll Health 1994; 42:271. |
|
12. |
|
Peroutka, SJ. Incidence of recreational use of 3,4-methylenedimethoxymethamphetamine (MDMA, 'ecstasy') on an undergraduate campus. N Engl J Med 1987; 317:1542. |
|
13. |
|
Webb, E, Ashton, CH, Kelly, P, Kamali, F. Alcohol and drug use in UK university students. Lancet 1996; 348:922. |
|
14. |
|
Buchanan, JF, Brown, CR. 'Designer drugs'. A problem in clinical toxicology. Med Toxicol Adverse Drug Exp 1988; 3:1. |
|
15. |
|
Gouzoulis-Mayfrank, E, Daumann, J, Tuchtenhagen, F, et al. Impaired cognitive performance in drug free users of recreational ecstasy (MDMA). J Neurol Neurosurg Psychiatry 2000; 68:719. |
|
16. |
|
Zakzanis, KK, Young, DA. Memory impairment in abstinent MDMA ("Ecstasy") users: A longitudinal investigation. Neurology 2001; 56:966. |
|
17. |
|
Reneman, L, Booij, J, de Bruin, K, et al. Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons. Lancet 2001; 358:1864. |
|
18. |
|
Eaton, DK, Kann, L, Kinchen, S. Youth risk behavior surveillance--United States, 2005. MMWR Surveill Summ 2006; 55:1. |
|
19. |
|
Johnston, LD, O'Malley, PM, Bachman, JG. The Monitoring the Future national results on adolescent drug use. National Institute on Drug Abuse, NIH, US Department of Health and Human Services, Bethesda, MD 1999. |
|
20. |
|
Ruttenber, AJ. Stalking the elusive designer drugs: Techniques for monitoring new problems in drug abuse. J Addict Dis 1991; 11:71. |
|
21. |
|
U.S. Department of Justice, Drug Enforcement Administration. Clandestine Laboratory Seizures in the United States. 1998. |
|
22. |
|
Poklis, A, Mackell, MA, Drake, WK. Fatal intoxication from 3,4-methylenedioxyamphetamine. J Forensic Sci 1979; 24:70. |
|
23. |
|
Ling, LH, Marchant, C, Buckley, NA, et al. Poisoning with the recreational drug paramethoxyamphetamine ("death"). Med J Aust 2001; 174:453. |
|
24. |
|
Liester, MB, Grob, CS, Bravo, GL, Walsh, RN. Phenomenology and sequelae of 3,4-methylenedioxymethamphetamine use. J Nerv Ment Dis 1992; 180:345. |
|
25. |
|
Wilkins, B. Cerebral oedema after MDMA ("ecstasy") and unrestricted water intake. Hyponatraemia must be treated with low water input. BMJ 1996; 313:689. |
|
26. |
|
Holmes, SB, Banerjee, AK, Alexander, WD. Hyponatraemia and seizures after ecstasy use. Postgrad Med J 1999; 75:32. |
|
27. |
|
Parr, MJ, Low, HM, Botterill, P. Hyponatraemia and death after "ecstasy" ingestion. Med J Aust 1997; 166:136. |
|
28. |
|
Lester, SJ, Baggott, M, Welm, S, et al. Cardiovascular effects of 3,4-methylenedioxymethamphetamine. A double-blind, placebo-controlled trial. Ann Intern Med 2000; 133:969. |
|
29. |
|
Gouzoulis, E, von Bardeleben, U, Rupp, A, et al. Neuroendocrine and cardiovascular effects of MDE in healthy volunteers. Neuropsychopharmacology 1993; 8:187. |
|
30. |
|
Winstock, AR, King, LA. Ecstasy and neurodegeneration. Tablets often contain substances in addition to, or instead of, ecstasy...[letter; comment]. BMJ 1996; 313:423. |
|
31. |
|
Manchanda, S, Connolly, MJ. Cerebral infarction in association with Ecstasy abuse. Postgrad Med J 1993; 69:874. |
|
32. |
|
Williams, H, Meagher, D, Galligan, P. M.D.M.A. ('Ecstasy'); a case of possible drug-induced psychosis. Ir J Med Sci 1993; 162:43. |
|
33. |
|
Marsh, JC, Abboudi, ZH, Gibson, FM, et al. Aplastic anaemia following exposure to 3,4-methylenedioxymethamphetamine ('Ecstasy'). Br J Haematol 1994; 88:281. |
|
34. |
|
O'Neill, D, Dart, JK. Methylenedioxyamphetamine ('Ecstasy') associated keratopathy. Eye 1993; 7 ( Pt 6):805. |
|
35. |
|
Rochester, JA, Kirchner, JT. Ecstasy (3,4-methylenedioxymethamphetamine): History, neurochemistry, and toxicology. J Am Board Fam Pract 1999; 12:137. |
|
36. |
|
Lai, TI, Hwang, JJ, Fang, CC, Chen, WJ. Methylene 3, 4 dioxymethamphetamine-induced acute myocardial infarction. Ann Emerg Med 2003; 42:759. |
|
37. |
|
Wijetunga, M, Seto, T, Lindsay, J, Schatz, I. Crystal methamphetamine-associated cardiomyopathy: tip of the iceberg?. J Toxicol Clin Toxicol 2003; 41:981. |
|
38. |
|
Byard, RW, Gilbert, J, James, R, Lokan, RJ. Amphetamine derivative fatalities in South Australia--is 'Ecstasy' the culprit? Am J Forensic Med Pathol 1998; 19:261. |
|
39. |
|
Arimany, J, Medallo, J, Pujol, A, et al. Intentional overdose and death with 3,4-methylenedioxyethamphetamine (MDEA; 'Eve'): case report. Am J Forensic Med Pathol 1998; 19:148. |
|
40. |
|
Tehan, B, Hardern, R, Bodenham, A. Hyperthermia associated with 3,4-methylenedioxyethamphetamine ('Eve'). Anaesthesia 1993; 48:507. |
|
41. |
|
Schifano, F, Oyefeso, A, Webb, L, et al. Review of deaths related to taking ecstasy, England and Wales, 1997-2000. BMJ 2003; 326:80. |
|
42. |
|
Walsh, T, Carmichael, R, Chestnut, J. A hyperthermic reaction to 'ecstasy'. Br J Hosp Med 1994; 51:476. |
|
43. |
|
Rejali, D, Glen, P, Odom, N. Pneumomediastinum following Ecstasy (methylenedioxymetamphetamine, MDMA) ingestion in two people at the same 'rave'. J Laryngol Otol 2002; 116:75. |
|
44. |
|
Rezvani, K, Kurbaan, AS, Brenton, D. Ecstasy induced pneumomediastinum. Thorax 1996; 51:960. |
|
45. |
|
Henry, JA, Jeffreys, KJ, Dawling, S. Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy") [see comments]. Lancet 1992; 340:384. |
|
46. |
|
Watson, JD, Ferguson, C, Hinds, CJ, et al. Exertional heat stroke induced by amphetamine analogues. Does dantrolene have a place? Anaesthesia 1993; 48:1057. |
|
47. |
|
Nimmo, SM, Kennedy, BW, Tullett, WM, et al. Drug-induced hyperthermia. Anaesthesia 1993; 48:892. |
|
48. |
|
Webb, C, Williams, V. Ecstasy intoxication: appreciation of complications and the role of dantrolene. Anaesthesia 1993; 48:542. |
|
49. |
|
Jones, AL, Volans, G. Management of self poisoning. BMJ 1999; 319:1414. |
|
50. |
|
Hibbs, J, Perper, J, Winek, CL. An outbreak of designer drug--related deaths in Pennsylvania. JAMA 1991; 265:1011. |
|
51. |
|
Brittain, JL. China white: the bogus drug. J Toxicol Clin Toxicol 1982; 19:1123. |
|
52. |
|
Ballard, PA, Tetrud, JW, Langston, JW. Permanent human Parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): Seven cases. Neurology 1985; 35:949. |
|
53. |
|
Davis, GC, Williams, AC, Markey, SP, et al. Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res 1979; 1:249. |
|
54. |
|
Langston, JW, Ballard, P, Tetrud, JW, Irwin, I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983; 219:979. |
|
55. |
|
Koesters, SC, Rogers, PD, Rajasingham, CR. MDMA ('ecstasy') and other 'club drugs'. The new epidemic. Pediatr Clin North Am 2002; 49:415. |
|
56. |
|
Weiner, AL, Vieira, L, McKay, CA, Bayer, MJ. Ketamine abusers presenting to the emergency department: a case series. J Emerg Med 2000; 18:447. |
|
57. |
|
Krystal, JH, Karper, LP, Seibyl, JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994; 51:199. |
|
58. |
|
Angelos, SA, Meyers, JA. The isolation and identification of precursors and reaction products in the clandestine manufacture of methaqualone and mecloqualone. J Forensic Sci 1985; 30:1022. |
|
59. |
|
Calkins, RF, Aktan, GB, Hussain, KL. Methcathinone: the next illicit stimulant epidemic? J Psychoactive Drugs 1995; 27:277. |
|
60. |
|
Emerson, TS, Cisek, JE. Methcathinone: A Russian designer amphetamine infiltrates the rural Midwest. Ann Emerg Med 1993; 22:1897. |
|
61. |
|
FDA warns consumers not to purchase green hornet promoted as herbal version of ecstasy. FDA News. (www.fda.gov/bbs/topics/NEWS/2004/NEW01026.html). |
|
62. |
|
Yates, KM, O'Connor, A, Horsley, CA. "Herbal Ecstasy": A case series of adverse reactions. N Z Med J 2000; 113:315. |
|
63. |
|
Doyon, S. The many faces of ecstasy. Curr Opin Pediatr 2001; 13:170. |
|
64. |
|
Chen, C, Biller, J, Willing, SJ, Lopez, AM. Ischemic stroke after using over the counter products containing ephedra. J Neurol Sci 2004; 217:55. |
|
||||||||||||
|
||||||||||||
|
printer-friendly
format
e-mail
this to a colleague
